Nucleix Bladder Epicheck Abstract To Be Featured In A Poster Discussion Session At The 2016 American Urological Association Annual Meeting On May 2016 In San Diego
Rehovot, Israel, April 24th 2016 – Nucleix, an innovative epigenetic cancer detection and screening company, announced today that the results of their latest Bladder EpiCheck study will be presented as a poster presentation in the next annual meeting of the American Urological Association (AUA). This meeting will be held in San Diego on May 6th-10th.
Bladder EpiCheck, Nucleix’s first product, is an IVD test for bladder cancer monitoring in urine samples. It includes 15 methylation biomarkers that are multiplexed together to achieve better performance – sensitivity, specificity and negative predictive value (NPV). The study that will be presented includes data of 222 patients with history of BC undergoing routine surveillance, and compared to the gold standard – cystoscopy and pathology. This study was performed at Meir Medical Center, and further validates Bladder EpiCheck’s performance in a clinical setting.
“We are proud to present our latest data at the AUA, which is the largest urology meeting in the world” said Dr. Adam Wasserstrom, Nucleix’s Co-founder and Vice President of Development. “We strongly believe that Bladder EpiCheck will be an integral tool in bladder cancer monitoring, as it provides excellent performance, while it requires less effort than current leading tests”
Bladder EpiCheck is not yet cleared for clinical use.
About Nucleix – Nucleix Ltd. develops, manufactures and markets innovative non-invasive molecular cancer diagnostic tests. Our highly sensitive and specific tests are based on identification of subtle changes in methylation patterns. Nucleix technology is based on a combination of a new biochemical platform in conjunction with sophisticated algorithms.
Our first product Bladder EpiCheck® is a urine test for monitoring of bladder cancer, and includes a panel of 15 proprietary biomarkers that are multiplexed in a real-time PCR analysis. This test has shown 90% sensitivity, 83% specificity and 97% NPV (based on a cohort of 221 patients that were monitored for recurrence by Prof. Ilan Leibovitch at Meir Medical Center in Israel) and it is expected to reach the market during 2016.
Nucleix pipeline includes diagnostic tests for lung and colorectal cancer detection from blood samples, using its proprietary and highly innovative technology.
Nucleix is backed up by leading investors including OrbiMed – the world’s largest bio-medical VC funds.
Bladder EpiCheck, Nucleix’s first product, is an IVD test for bladder cancer monitoring in urine samples. It includes 15 methylation biomarkers that are multiplexed together to achieve better performance – sensitivity, specificity and negative predictive value (NPV). The study that will be presented includes data of 222 patients with history of BC undergoing routine surveillance, and compared to the gold standard – cystoscopy and pathology. This study was performed at Meir Medical Center, and further validates Bladder EpiCheck’s performance in a clinical setting.
“We are proud to present our latest data at the AUA, which is the largest urology meeting in the world” said Dr. Adam Wasserstrom, Nucleix’s Co-founder and Vice President of Development. “We strongly believe that Bladder EpiCheck will be an integral tool in bladder cancer monitoring, as it provides excellent performance, while it requires less effort than current leading tests”
Bladder EpiCheck is not yet cleared for clinical use.
About Nucleix – Nucleix Ltd. develops, manufactures and markets innovative non-invasive molecular cancer diagnostic tests. Our highly sensitive and specific tests are based on identification of subtle changes in methylation patterns. Nucleix technology is based on a combination of a new biochemical platform in conjunction with sophisticated algorithms.
Our first product Bladder EpiCheck® is a urine test for monitoring of bladder cancer, and includes a panel of 15 proprietary biomarkers that are multiplexed in a real-time PCR analysis. This test has shown 90% sensitivity, 83% specificity and 97% NPV (based on a cohort of 221 patients that were monitored for recurrence by Prof. Ilan Leibovitch at Meir Medical Center in Israel) and it is expected to reach the market during 2016.
Nucleix pipeline includes diagnostic tests for lung and colorectal cancer detection from blood samples, using its proprietary and highly innovative technology.
Nucleix is backed up by leading investors including OrbiMed – the world’s largest bio-medical VC funds.